½ÃÀ庸°í¼­
»óǰÄÚµå
1334630

¼¼°èÀÇ ¹«Ç÷û ¹èÁö ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç°, ¿ëµµ, À¯Çü, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Serum-free Media Market Size study & Forecast, by Product, by Application, by Type, by End-User and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¹«Ç÷û ¹èÁö ½ÃÀåÀº 2022³â ¾à 14¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 13.03% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹«Ç÷û ¹èÁö´Â ¼¼Æ÷ÀÇ ¼ºÀåÀ» À§ÇØ µ¿¹°ÀÇ Ç÷ûÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ ÀûÀýÇÑ ºñÀ²ÀÇ ¿µ¾ç¼Ò¿Í È£¸£¸óÀ» ÇÔÀ¯Çϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ ¹è¾ç¿ë ¹«Ç÷û ¹èÁö´Â »ý»ê¼º ¹× Àϰü¼º Çâ»ó, Á¤Á¦ ¹× ´Ù¿î½ºÆ®¸² ó¸® ¿ëÀ̼º µî ¸¹Àº ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹«Ç÷û ¹èÁö Á¦Á¦´Â ƯÁ¤ ¼¼Æ÷ À¯Çü¿¡ ´ëÇÑ ¼±ÅÃÀû Áõ½ÄÁ¦¸¦ Á¶ÇÕÇÏ¿© Æ÷ÇÔÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹«Ç÷û ¹èÁö Á¦Á¦´Â ÇÏÀ̺긮µµ¸¶ ¼¼Æ÷ÁÖ, ÀçÁ¶ÇÕ ´Ü¹éÁúÀ» »ý»êÇÏ´Â Áß±¹ ÇܽºÅÍ ³­¼Ò(CHO) ¼¼Æ÷ÁÖ, ¹ÙÀÌ·¯½º »ý»ê ¼÷ÁÖ ¼¼Æ÷ÁÖ(293, VERO, MDCK, MDBK µî)¸¦ Æ÷ÇÔÇÑ ¸¹Àº 1Â÷ ¹è¾ç ¹× ¼¼Æ÷ÁÖ¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹«Ç÷û ¹èÁö ½ÃÀåÀÇ ¼ºÀåÀº ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦¿¡ ´ëÇÑ °ü½É Áõ°¡, »õ·Î¿î ¹ÙÀÌ¿ÀÀǾàǰÀÇ »ý»ê Áõ°¡, ¼¼Æ÷ ¹è¾ç¿¡¼­ CHO ¼¼Æ÷¸¦ ÀÌ¿ëÇÑ ´ë±Ô¸ð »ý»ê µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

Statista¿¡ µû¸£¸é, ¼¼°è ¼¼Æ÷ ¹è¾ç ½ÃÀåÀº 2022³â ¾à 192¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â±îÁö CAGR 7.2%·Î 330¾ï ´Þ·¯ ÀÌ»óÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, FDA ½ÂÀÎ ¹× ÀÓ»ó½ÃÇè Áõ°¡, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °øµ¿ ¿¬±¸¿Í °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê°¡ ½ÃÀåÀ» È®´ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀåÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áٱ⼼Æ÷ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡¿Í ¹Ìµð¾î¸¦ ÅëÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå¿¡ dzºÎÇÑ ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Regenerative Medicine)Àº ½ÉºÎÀü, ³úÁ¹Áß, ƯÁ¤ ô¼öÁ¾¾ç ¹× ³úÁ¾¾ç Ä¡·á¸¦ À§ÇÑ Àΰ£ ÃÖÃÊÀÇ Áٱ⼼Æ÷ ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇϱâ À§ÇØ ½ºÅÄÆ÷µå ´ëÇÐÀÇ ÀÇ»ç ¿¬±¸¿øµé¿¡°Ô ¾à 3,100¸¸ ´Þ·¯¸¦ Áö¿øÇß½À´Ï´Ù. ±×·¯³ª »ý»ê °øÁ¤°ú ³ôÀº R&D ºñ¿ëÀº 2023-2030³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â °­·ÂÇÑ R&D ÀÎÇÁ¶ó¿Í ¿ìÈ£Àû ÀÎ ±ÔÁ¦ ȯ°æÀÇ Á¸Àç·Î ÀÎÇØ 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, ÈÄÁöÇʸ§ Ȧµù½º´Â 2022³â 11¿ù ³ë½ºÄ³·Ñ¶óÀ̳ªÁÖ ¸®¼­Ä¡ Æ®¶óÀÌ¾Þ±Û ÆÄÅ©(RTP)¿¡ 1¾ï 8,800¸¸ ´Þ·¯¸¦ ÅõÀÚÇÏ¿© ¹«Ç÷û ¹èÁö Á¦Á¶ °øÀåÀ» °Ç¼³Çß½À´Ï´Ù. ±×·¯³ª ¸¸¼º ¹× ÁßÁõ Áúȯ¿¡ ´ëÇÑ ¿¬±¸°³¹ß ¹× ÀÓ»ó½ÃÇè ÇÁ·Î±×·¥ÀÌ ¸Å³â Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï »óȲ°ú Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¹«Ç÷û ¹èÁö ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°èÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó ¿¬µµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå ¿ªÇÐ

  • ¹«Ç÷û ¹èÁö ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦¿¡ ´ëÇÑ ÁÖ¸ñ »ó½Â
      • ½Å±Ô ¹ÙÀÌ¿ÀÀǾàǰ »ý»ê È®´ë
      • ¼¼Æ÷¹è¾ç¿¡ ÀÇÇÑ ´ë±Ô¸ð Á¦Á¶
    • ½ÃÀå °úÁ¦
      • »ý»ê °øÁ¤ÀÇ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • Áٱ⼼Æ÷ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡
      • ¹èÁö ±â¹Ý Áø´Ü °Ë»ç¿¡ ´ëÇÑ ÀÎ½Ä È®»ê

Á¦4Àå ¼¼°èÀÇ ¹«Ç÷û ¹èÁö ½ÃÀå : »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
  • Porter's 5 Force ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦5Àå ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ÇöȲ
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : Á¦Ç°º°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹«Ç÷û ¹èÁö ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • CHO ¹èÁö
    • HEK 293¹èÁö
    • BHK ¹èÁö
    • Vero ¹èÁö
    • Áٱ⼼Æ÷ ¹èÁö
    • ±âŸ ¹«Ç÷û ¹èÁö

Á¦6Àå ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¹ÙÀÌ¿ÀÀǾàǰ »ý»ê
    • ´ÜŬ·ÐÇ×ü
    • ¹é½Å »ý»ê
    • Á¶Á÷°øÇС¤Àç»ýÀÇ·á
    • ±âŸ Ä¡·á¿ë ´Ü¹éÁú

Á¦7Àå ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : À¯Çüº°

  • ½ÃÀå ÇöȲ
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : À¯Çüº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¾×ü ¹èÁö
    • ¹Ý°íü ¹èÁö¡¤°íü ¹èÁö

Á¦8Àå ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ÇöȲ
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹«Ç÷û ¹èÁö ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • Á¦¾à ±â¾÷¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • ¿¬±¸±â°ü ¹× Çмú±â°ü
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ¹«Ç÷û ¹èÁö ¼¼°è ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ¹«Ç÷û ¹èÁö ½ÃÀå Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ¿ëµµ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ ¹«Ç÷û ¹èÁö ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹«Ç÷û ¹èÁö ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¹«Ç÷û ¹èÁö ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Sartorius AG
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
      • Á¦Ç° °³¿ä
      • ÃÖ±ÙÀÇ µ¿Çâ
    • FUJIFILM Holdings Corporation
    • Lonza Group AG
    • STEMCELL Technologies
    • PromoCell GmbH
    • Thermo Fisher Scientific Inc.
    • Corning Incorporated
    • FUJIFILM Irvine Scientific
    • Athena Environmental Sciences
    • Sartorius CellGenix

Á¦11Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç °¡Á¤
ksm 23.09.19

Global Serum-free Media Market is valued approximately at USD 1.46 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 13.03% over the forecast period 2023-2030. Serum-free media contains proper ratios of nutrients and hormones because they don't require animal serum for cell growth. Serum-free media for cell culture has a number of advantages, including increased productivity and consistency as well as easier purification and downstream processing. In addition, serum-free media formulations can contain combinations of selective growth agents for specific cell types. Serum-free medium formulations are available for many primary cultures and cell lines, including hybridoma cell lines, Chinese hamster ovary (CHO) lines that produce recombinant proteins, and cell lines that act as hosts for virus production (e.g., 293, VERO, MDCK, MDBK). The market growth of serum-free media is driven by factors such as rising focus on cell-based therapeutics, growing production of new biopharmaceuticals and large scale manufacturing with CHO cells in cell culture.

According to Statista, the global cell culture market reached around USD 19.2 billion in 2022 and it is expected that by 2030, the market would be worth more than USD 33 billion, with a CAGR of 7.2%. More FDA approvals, clinical trials, and strategic initiatives such collaborations by the key market players is expanding the market. Moreover, increasing funding in stem cell research and rising awareness of media-based diagnostic testing may create abundant opportunities for the market in the forecast years. In September 2021, the California Institute for Regenerative Medicine awarded Stanford physician-researchers almost USD 31.0 million to begin the first-in-human stem cell clinical trials for the treatment of heart failure, stroke, and a specific form of spinal cord and brain tumor. However, the high cost of production process and high research and Development costs may stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Serum-free Media Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share due to the existence of a strong R&D infrastructure and a supportive regulatory environment, both of which are quickly changing to accommodate the sector's continual scientific advancement. For instance, in November 2022, FUJIFILM Holdings Corporation invested USD 188.0 million in Research Triangle Park (RTP), North Carolina, to construct a manufacturing plant for serum-free media. However, Asia Pacific is expected to be the fastest growing region during the forecast period, due to more R&D and clinical trial programs for chronic and serious illnesses every year.

Major market player included in this report are:

  • Sartorius AG
  • FUJIFILM Holdings Corporation
  • Lonza Group AG
  • STEMCELL Technologies
  • PromoCell GmbH
  • Thermo Fisher Scientific Inc.
  • Corning Incorporated
  • FUJIFILM Irvine Scientific
  • Athena Environmental Sciences
  • Sartorius CellGenix

Recent Developments in the Market:

  • In November 2022, BioPharma Dynamics expanded their product range for the Gene & Cell Therapy sector to offer a range of serum-free and chemically specified cell medium solutions. The selection of cell media products comprises cell cryopreservation solutions, stem cell media, and immune cell media, all of which are appropriate for cell therapy applications.
  • In August 2022, Thermo Fisher Scientific Inc. expanded the cell culture media manufacturing plant in Grand Island, New York in order to enable the production of fresh vaccines and biologics.
  • In July 2022, Moderna, Inc. and Thermo Fisher Scientific Inc. entered a 15-year strategic collaboration agreement in order to facilitate the dedicated large-scale manufacturing of Spikevax, Moderna's COVID-19 vaccine, and other investigational mRNA therapies in its pipelines in the United States.

Global Serum-free Media Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Application, Type, End-User, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product:

  • CHO Media
  • HEK 293 Media
  • BHK Media
  • Vero Media
  • Stem Cell Media
  • Other Serum-free Media

By Application:

  • Biopharmaceutical Production
  • Monoclonal Antibodies
  • Vaccines Production
  • Tissue Engineering & Regenerative Medicine
  • Other Therapeutic Proteins

By Type:

  • Liquid Media
  • Semi-solid & Solid Media

By End-User:

  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Other End-Users

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Serum-free Media Market, by region, 2020-2030 (USD Billion)
    • 1.2.2. Serum-free Media Market, by Product, 2020-2030 (USD Billion)
    • 1.2.3. Serum-free Media Market, by Application, 2020-2030 (USD Billion)
    • 1.2.4. Serum-free Media Market, by Type, 2020-2030 (USD Billion)
    • 1.2.5. Serum-free Media Market, by End-User, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Serum-free Media Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Serum-free Media Market Dynamics

  • 3.1. Serum-free Media Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising focus on cell-based therapeutics
      • 3.1.1.2. Growing production of new biopharmaceuticals
      • 3.1.1.3. Large Scale Manufacturing with cell culture
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Production Process
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing funding in stem cell research
      • 3.1.3.2. Rising awareness of media-based testing of diagnostic

Chapter 4. Global Serum-free Media Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Serum-free Media Market, by Product

  • 5.1. Market Snapshot
  • 5.2. Global Serum-free Media Market by Product, Performance - Potential Analysis
  • 5.3. Global Serum-free Media Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 5.4. Serum-free Media Market, Sub Segment Analysis
    • 5.4.1. CHO Media
    • 5.4.2. HEK 293 Media
    • 5.4.3. BHK Media
    • 5.4.4. Vero Medium
    • 5.4.5. Stem Cell Medium
    • 5.4.6. Other Serum-free Media

Chapter 6. Global Serum-free Media Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Serum-free Media Market by Application, Performance - Potential Analysis
  • 6.3. Global Serum-free Media Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Serum-free Media Market, Sub Segment Analysis
    • 6.4.1. Biopharmaceutical Production
    • 6.4.2. Monoclonal Antibodies
    • 6.4.3. Vaccines Production
    • 6.4.4. Tissue Engineering & Regenerative Medicine
    • 6.4.5. Other Therapeutic Proteins

Chapter 7. Global Serum-free Media Market, by Type

  • 7.1. Market Snapshot
  • 7.2. Global Serum-free Media Market by Type, Performance - Potential Analysis
  • 7.3. Global Serum-free Media Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
  • 7.4. Serum-free Media Market, Sub Segment Analysis
    • 7.4.1. Liquid Media
    • 7.4.2. Semi-solid & Solid Media

Chapter 8. Global Serum-free Media Market, by End-User

  • 8.1. Market Snapshot
  • 8.2. Global Serum-free Media Market by End-User, Performance - Potential Analysis
  • 8.3. Global Serum-free Media Market Estimates & Forecasts by End-User 2020-2030 (USD Billion)
  • 8.4. Serum-free Media Market, Sub Segment Analysis
    • 8.4.1. Pharmaceutical & Biotechnology Companies
    • 8.4.2. Research & Academic Institutes
    • 8.4.3. Other End-Users

Chapter 9. Global Serum-free Media Market, Regional Analysis

  • 9.1. Top Leading Countries
  • 9.2. Top Emerging Countries
  • 9.3. Serum-free Media Market, Regional Market Snapshot
  • 9.4. North America Serum-free Media Market
    • 9.4.1. U.S. Serum-free Media Market
      • 9.4.1.1. Product breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3. Type breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4. End-User breakdown estimates & forecasts, 2020-2030
    • 9.4.2. Canada Serum-free Media Market
  • 9.5. Europe Serum-free Media Market Snapshot
    • 9.5.1. U.K. Serum-free Media Market
    • 9.5.2. Germany Serum-free Media Market
    • 9.5.3. France Serum-free Media Market
    • 9.5.4. Spain Serum-free Media Market
    • 9.5.5. Italy Serum-free Media Market
    • 9.5.6. Rest of Europe Serum-free Media Market
  • 9.6. Asia-Pacific Serum-free Media Market Snapshot
    • 9.6.1. China Serum-free Media Market
    • 9.6.2. India Serum-free Media Market
    • 9.6.3. Japan Serum-free Media Market
    • 9.6.4. Australia Serum-free Media Market
    • 9.6.5. South Korea Serum-free Media Market
    • 9.6.6. Rest of Asia Pacific Serum-free Media Market
  • 9.7. Latin America Serum-free Media Market Snapshot
    • 9.7.1. Brazil Serum-free Media Market
    • 9.7.2. Mexico Serum-free Media Market
  • 9.8. Middle East & Africa Serum-free Media Market
    • 9.8.1. Saudi Arabia Serum-free Media Market
    • 9.8.2. South Africa Serum-free Media Market
    • 9.8.3. Rest of Middle East & Africa Serum-free Media Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Company 1
    • 10.1.2. Company 2
    • 10.1.3. Company 3
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Sartorius AG
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Recent Developments
    • 10.3.2. FUJIFILM Holdings Corporation
    • 10.3.3. Lonza Group AG
    • 10.3.4. STEMCELL Technologies
    • 10.3.5. PromoCell GmbH
    • 10.3.6. Thermo Fisher Scientific Inc.
    • 10.3.7. Corning Incorporated
    • 10.3.8. FUJIFILM Irvine Scientific
    • 10.3.9. Athena Environmental Sciences
    • 10.3.10. Sartorius CellGenix

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦